MIRA Pharmaceuticals
MIRA
24 hedge funds and large institutions have $2.22M invested in MIRA Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.
344% more capital inflows, than outflows
Capital inflows: $332K | Capital outflows: $74.7K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.76% more ownership
Funds ownership: 5.51% → 6.27% (+0.76%)
11% less funds holding
Funds holding: 27 → 24 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$169K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$86.5K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$41.3K |
| 4 |
State Street
Boston,
Massachusetts
|
+$22.9K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$9.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$24.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.6K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$15.5K |
| 4 |
HRT Financial
New York
|
-$12K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$1.82K |
MIRA Hedge Fund Activity: Q3 2026 in Review
24 of the 8,221 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q3 2026, worth a combined $2.22M — up 1.4% from $2.19M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MIRA and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, adding an estimated $169K. The largest seller was BlackRock, cutting an estimated $24.3K.
- 24 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q3 2026, down from 27 in Q2 2026.
- Funds reported $2.22M of MIRA Pharmaceuticals stock for Q3 2026, up 1.4% quarter-over-quarter.
- 3 funds opened new MIRA Pharmaceuticals positions in Q3 2026 and 6 closed out, a net change of -3 holders.
- The largest MIRA Pharmaceuticals buyer in Q3 2026 was Citadel Advisors, an estimated $169K added.
- The largest MIRA Pharmaceuticals seller in Q3 2026 was BlackRock, an estimated $24.3K sold.
Based on aggregated 13F filings for Q3 2026.